uBriGene’s LVV Turbo™ lentivirus production platform integrates three cutting-edge technologies to deliver higher-yield, high-potency lentivirus at lower cost.
Download Brochure
RNA-LNP vs. Sendai virus: What does the evidence show? Download the webinar slides to explore the data behind next-generation PBMC-to-iPSC reprogramming.
Download the webinar slides for expert insights into circRNA design, circularization, purification, and manufacturing challenges, and strategies to advance circRNA therapeutics toward clinical translation.
Explore the key strategies and technical insights shared by uBriGene and Senlang Bio to advance targeted T-cell delivery and high-titer LVV manufacturing for in vivo CAR-T.
Compare RNA-LNP vs. Sendai virus for PBMC-to-iPSC reprogramming. Learn how RNA-LNP enables faster workflows, lower costs, and high-quality iPSC generation.
Discover how uVivo™ LVV is advancing the next generation of in vivo CAR-T therapy with targeted T-cell delivery, rapid in vivo CAR-T generation, and scalable off-the-shelf potential.
Explore FDA-registered manufacturing, premium MSC, exosome, and EV products, plus scalable, compliant solutions backed by 10+ years of cGMP expertise.
Learn how cutting-edge technologies to alleviate lentiviral supply constraints, reduce manufacturing costs, and support seamless scale-up from early development through commercial readiness.
Delivering high-quality TIL manufacturing globally, uBriGene Biosciences combines automation, scalability, and precision with over 10 successful GMP batches.
Learn how uBriGene can deliver high efficiency total solution designed to accelerate the development of iPSC-derived cell therapies.
Unlock safer regenerative therapies with uBriGene’s Genome-Safe iPSC reprogramming built for clinical success.